PDF (Español)
FLIP
Publication Date: 2014-12-19
How to Cite
Guzmán Terán, C., Villa Dangond, H., & Torres Ayazo, O. (2014). Aggressive scaly erytroderma, adverse reaction in a patient treated with hydrochlorothiazide: A case report. Biosalud, 13(2), 113–117. Retrieved from https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/4678
More Citation Formats
Authors
Abstract
The clinical case of a 69 year old man having high blood pressure who was treated with hydrochlorothiazide at 25 mg per day and who developed an adverse reaction compatible with scaly erythroderma is described. The patient underwent clinical recovery and total solution to his skin problems when the use of hydrochlorothiazide was susupended.
Keywords:
References
Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46-54.
Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168.
Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96.
Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195.
Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419.
Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012.
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.
Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7.
Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938.
Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7.
Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51.
Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31.
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472.
Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124.
Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120.
Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616.
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771.
Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92.
Dormann H, Mulh-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization: Computerized monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22:161-168.
Chang YP, Huang SK, Tao P, Chien CW. A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy. BMC Nephrology 2012; 13:96.
Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug related problems. Br J Clin Pharmacol 2007; 63:187-195.
Moya Y, Bernal F, Rojas E, Barthel E. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol 2012; 29 (4): 412-419.
Product Information. Tekturna HCT(R) oral tablets, aliskiren hydrochlorothiazide oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2012.
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.
Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring. Center. J Rheumatol 2001; 28:1180-7.
Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013; 8(7):e68938.
Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn B, Dubois EL, et al., eds. Dubois’ Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007; 7.
Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49-51.
Richard R, Tigh J, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and Cutaneous T Cell Lymphoma Prospective Analysis and Case Series. Cancer 2013; 119:825-31.
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus British Journal of Dermatology 2011; 164:465-472.
Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed 2000; 16:121-124.
Bartolo L, Valverde J, Rojas P, Vicuña D. Eritrodermia adquirida en un adulto. Dermatol Perú 2010; 20(1):116-120.
Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosisfungoidesa disease of antigen persistence. Br J Dermatol 1974; 91:607-616.
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767-771.
Schjott J, Bergman J. Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety 2014; 6:89-92.
Downloads
Download data is not yet available.
